CStone Pharma's CS2009 Tri-Specific Antibody Data Accepted for ESMO 2026 Presentation

Stock News07-20

Clinical findings for CSTONE PHARMA-B (ASX: 02616)'s key asset, CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody), have been selected for presentation at the 2026 European Society for Medical Oncology (ESMO) Congress.

The data will be delivered via two rapid oral presentations. These will cover Phase I/II clinical trial results for CS2009 in patients with advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).

The titles for these abstracts are now available on the official ESMO website. It is important to note that the data within these abstracts is current only up to April 2026, in line with the congress submission deadline.

The company plans to present more recent clinical data, with a cut-off date closer to the event, at the ESMO Congress itself, which is scheduled to take place in Madrid, Spain, from October 23 to 26, 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146705632?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 08:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146705632","market":"us","top_or_hot":-1,"title":"CStone Pharma's CS2009 Tri-Specific Antibody Data Accepted for ESMO 2026 Presentation","media":"Stock News","content":"<p>Clinical findings for <b>CSTONE PHARMA-B</b> (<b>ASX: 02616</b>)'s key asset, CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody), have been selected for presentation at the 2026 European Society for Medical Oncology (ESMO) Congress.<br><br>The data will be delivered via two rapid oral presentations. These will cover Phase I/II clinical trial results for CS2009 in patients with advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).<br><br>The titles for these abstracts are now available on the official ESMO website. It is important to note that the data within these abstracts is current only up to April 2026, in line with the congress submission deadline.<br><br>The company plans to present more recent clinical data, with a cut-off date closer to the event, at the ESMO Congress itself, which is scheduled to take place in Madrid, Spain, from October 23 to 26, 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone Pharma's CS2009 Tri-Specific Antibody Data Accepted for ESMO 2026 Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone Pharma's CS2009 Tri-Specific Antibody Data Accepted for ESMO 2026 Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-20 08:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clinical findings for <b>CSTONE PHARMA-B</b> (<b>ASX: 02616</b>)'s key asset, CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody), have been selected for presentation at the 2026 European Society for Medical Oncology (ESMO) Congress.<br><br>The data will be delivered via two rapid oral presentations. These will cover Phase I/II clinical trial results for CS2009 in patients with advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).<br><br>The titles for these abstracts are now available on the official ESMO website. It is important to note that the data within these abstracts is current only up to April 2026, in line with the congress submission deadline.<br><br>The company plans to present more recent clinical data, with a cut-off date closer to the event, at the ESMO Congress itself, which is scheduled to take place in Madrid, Spain, from October 23 to 26, 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169590202.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"","article_id":"1146705632","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146705632","pubTimestamp":1784506218,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Clinical findings for CSTONE PHARMA-B (ASX: 02616)'s key asset, CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody), have been selected for presentation at the 2026 European Society for Medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4023":"应用软件","BK1574":"生物医药B类股","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","PD":"PagerDuty, Inc.","BK1161":"生物科技","02616":"基石药业-B"},"translate_title":"基石医药的CS2009三特异性抗体数据被接受用于ESMO 2026演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"02616":1},"content_text":"Clinical findings for CSTONE PHARMA-B (ASX: 02616)'s key asset, CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody), have been selected for presentation at the 2026 European Society for Medical Oncology (ESMO) Congress.The data will be delivered via two rapid oral presentations. These will cover Phase I/II clinical trial results for CS2009 in patients with advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).The titles for these abstracts are now available on the official ESMO website. It is important to note that the data within these abstracts is current only up to April 2026, in line with the congress submission deadline.The company plans to present more recent clinical data, with a cut-off date closer to the event, at the ESMO Congress itself, which is scheduled to take place in Madrid, Spain, from October 23 to 26, 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146705632","isCrawlerRequest":true}